Showing 1,021 - 1,040 results of 104,438 for search '(( 5 ((((nm decrease) OR (a decrease))) OR (nn decrease)) ) OR ( 2 de decrease ))', query time: 1.43s Refine Results
  1. 1021

    Bidirectional Optical Control of Proton Motive Force in Escherichia coli Using Microbial Rhodopsins by Kotaro Nakanishi (3389300)

    Published 2024
    “…Tethered cell experiments revealed that, upon illumination, the torque of the flagellar motor decreased to nearly zero (28 pN nm) with <i>Rm</i>XeR, while it increased to 1170 pN nm with AR3. …”
  2. 1022
  3. 1023
  4. 1024
  5. 1025
  6. 1026
  7. 1027
  8. 1028
  9. 1029
  10. 1030
  11. 1031
  12. 1032
  13. 1033
  14. 1034

    Table_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  15. 1035

    Table_3_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  16. 1036

    Table_4_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.XLSX by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  17. 1037

    Image_1_Beneficial Effect of a Selective Adenosine A2A Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of Alzheimer’s Disease.PDF by Emilie Faivre (5507582)

    Published 2018
    “…In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A<sub>2A</sub>R antagonist MSX-3 from 3 to 9-10 months of age. …”
  18. 1038
  19. 1039
  20. 1040